Key Differences Between Wegovy 1.7mg and Mounjaro
1.7mg Wegovy vs Mounjaro: UK Stock Availability Comparison
The availability of 1.7mg Wegovy vs Mounjaro has transformed significantly in 2026, with both treatments now readily available through UK-registered pharmacies. EverydayMeds maintains consistent stock levels of Wegovy 1.7mg at £139.99, eliminating the historical waiting periods that affected treatment continuity. Our direct supply partnership with Novo Nordisk ensures reliable access to all five Wegovy doses, including the critical 1.7mg transition phase before maintenance.
Mounjaro availability has similarly stabilised, offering patients genuine choice between semaglutide and tirzepatide mechanisms. The decision between 1.7mg Wegovy vs Mounjaro often comes down to individual response patterns, storage convenience, and dosing preferences rather than availability constraints. Both treatments require the same 3-minute clinical assessment process, with prescriber review completed within standard timeframes and next-day delivery via temperature-controlled logistics.
Pricing Structure: 1.7mg Wegovy vs Mounjaro Cost Analysis
When comparing 1.7mg Wegovy vs Mounjaro pricing, Wegovy 1.7mg costs £139.99 as a single pen, representing excellent value for the penultimate dose in your escalation journey. The Elevate Duo bundle (1.7mg + 2.4mg) at £369.99 provides seamless transition to maintenance, whilst the Consistency 1.7mg bundle (×2) offers £309.99 for extended treatment at this dose level. Returning customers benefit from the DOSE25 discount code applied at checkout, maintaining competitive pricing throughout their weight management journey.
Mounjaro follows its own pricing structure, though direct cost comparison between 1.7mg Wegovy vs Mounjaro requires consideration of dosing equivalence and treatment duration. The 1.7mg Wegovy dose specifically covers weeks 13-16, positioning patients perfectly for the final step to 2.4mg maintenance. This predictable progression allows accurate budgeting for long-term treatment, particularly when utilizing bundle options that secure future supply at current pricing.
Clinical Evidence: 1.7mg Wegovy vs Mounjaro Mechanism Differences
The fundamental difference in 1.7mg Wegovy vs Mounjaro lies in their receptor targets—Wegovy contains semaglutide, a selective GLP-1 receptor agonist, whilst Mounjaro utilises tirzepatide, targeting both GLP-1 and GIP receptors. In the STEP trials, patients taking Wegovy alongside diet and exercise achieved approximately 15% average weight loss at 68 weeks (Wilding et al., NEJM, 2021). The 1.7mg dose represents a crucial escalation point where therapeutic effects typically accelerate before reaching maintenance levels.
Mounjaro's dual mechanism may offer different appetite suppression patterns, though direct comparison between 1.7mg Wegovy vs Mounjaro requires careful consideration of dose equivalence and individual response variability. Both treatments work on brain appetite centres to reduce food cravings and promote satiety after smaller meals, supporting sustainable weight management when combined with lifestyle modifications.
How Wegovy 1.7mg Works in Your Treatment Journey
Wegovy functions as a GLP-1 receptor agonist, mimicking natural incretin hormones that regulate appetite and blood glucose levels. The 1.7mg dose intensifies these effects compared to earlier escalation phases, typically producing more pronounced appetite reduction and improved satiety signals. This mechanism works directly on hypothalamic appetite centres, reducing food cravings whilst enhancing the feeling of fullness after meals. The once-weekly injection schedule maintains consistent therapeutic levels, supporting behavioural changes necessary for long-term weight management. When comparing 1.7mg Wegovy vs Mounjaro mechanisms, both ultimately achieve appetite suppression, though through different receptor pathways that may suit individual patient profiles differently.
Ordering Process for 1.7mg Wegovy vs Mounjaro
Accessing either treatment begins with our 3-minute online clinical assessment, designed to evaluate your suitability for 1.7mg Wegovy vs Mounjaro based on current medical history and treatment goals. Our UK-registered prescribers (GPhC #9012878) review applications within standard 3 working days, or express 24-hour service for urgent requirements. Once approved, both treatments ship via next-day delivery using specialized cold-chain logistics maintaining 2-8°C temperature control throughout transport. The ordering process remains identical whether choosing Wegovy or Mounjaro, though your clinical assessment responses help determine the most appropriate option. Payment processing accepts all major methods, with discount codes FIRST40 (new customers) or DOSE25 (returning customers) applied automatically at checkout.
Storage and Practical Considerations: 1.7mg Wegovy vs Mounjaro
Storage requirements significantly differentiate 1.7mg Wegovy vs Mounjaro in practical usage scenarios. Wegovy maintains stability for 6 weeks at room temperature below 30°C once removed from refrigeration, compared to Mounjaro's 21-day limit—a substantial advantage for travel or lifestyle flexibility. Both treatments require initial refrigerated storage at 2-8°C, arriving in temperature-controlled packaging to maintain efficacy. The FlexTouch pen system used for Wegovy provides intuitive dose delivery with clear dosing increments and safety features. Weekly injection timing remains consistent regardless of which treatment you choose, though the extended room temperature stability of Wegovy often influences patient preference for 1.7mg Wegovy vs Mounjaro, particularly for those with busy lifestyles or frequent travel commitments.
1.7mg Wegovy vs Mounjaro: Strategic Treatment Planning
The choice between 1.7mg Wegovy vs Mounjaro at this dose level reflects strategic long-term planning rather than immediate availability concerns. Patients reaching 1.7mg Wegovy are just four weeks from maintenance therapy, making treatment consistency crucial for optimal outcomes. The established escalation pathway provides predictable progression, whilst Mounjaro's different dose titration schedule may require alternative planning considerations.
Treatment switching between 1.7mg Wegovy vs Mounjaro typically requires prescriber consultation to ensure appropriate dose equivalence and minimize potential side effects. The investment in consistent supply through bundle options becomes particularly valuable at this advanced stage, where treatment interruption could compromise achieved progress. Both treatments remain available without supply constraints, allowing genuine choice based on clinical appropriateness rather than availability pressures.
Secure Your Treatment: 1.7mg Wegovy vs Mounjaro Available Now
Both 1.7mg Wegovy vs Mounjaro remain in stock with immediate dispatch capability, eliminating historical supply anxieties that affected treatment continuity. New customers use code FIRST40 whilst returning patients benefit from DOSE25, ensuring optimal pricing throughout your weight management journey. Our clinical team stands ready to support your treatment selection, whether continuing with Wegovy 1.7mg at £139.99 or exploring Mounjaro alternatives. Visit https://everydaymeds.co.uk/products/wegovy-1-7mg to begin your clinical assessment today. The prescription-only medicine requires professional oversight, supported by our GPhC-registered pharmacy services committed to safe, effective weight management outcomes alongside comprehensive lifestyle support.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
